
Yevgeny Valenrod
Examiner (ID: 18322)
| Most Active Art Unit | 1621 |
| Art Unit(s) | 1628, 1621, 1672 |
| Total Applications | 1499 |
| Issued Applications | 1070 |
| Pending Applications | 102 |
| Abandoned Applications | 358 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 18815899
[patent_doc_number] => 20230390238
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-12-07
[patent_title] => ENHANCING AUTOPHAGY OR INCREASING LONGEVITY BY ADMINISTRATION OF UROLITHINS
[patent_app_type] => utility
[patent_app_number] => 18/205305
[patent_app_country] => US
[patent_app_date] => 2023-06-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 79595
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18205305
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/205305 | ENHANCING AUTOPHAGY OR INCREASING LONGEVITY BY ADMINISTRATION OF UROLITHINS | Jun 1, 2023 | Pending |
Array
(
[id] => 18646984
[patent_doc_number] => 20230292751
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-09-21
[patent_title] => CONTROL OF RESISTANT PESTS
[patent_app_type] => utility
[patent_app_number] => 18/322174
[patent_app_country] => US
[patent_app_date] => 2023-05-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14771
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 162
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18322174
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/322174 | CONTROL OF RESISTANT PESTS | May 22, 2023 | Pending |
Array
(
[id] => 18628154
[patent_doc_number] => 20230286993
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-09-14
[patent_title] => CYCLIC ETHER DERIVATIVES OF PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXYAMIDE
[patent_app_type] => utility
[patent_app_number] => 18/320264
[patent_app_country] => US
[patent_app_date] => 2023-05-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22663
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 341
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18320264
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/320264 | Cyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxyamide | May 18, 2023 | Issued |
Array
(
[id] => 18628154
[patent_doc_number] => 20230286993
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-09-14
[patent_title] => CYCLIC ETHER DERIVATIVES OF PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXYAMIDE
[patent_app_type] => utility
[patent_app_number] => 18/320264
[patent_app_country] => US
[patent_app_date] => 2023-05-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22663
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 341
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18320264
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/320264 | Cyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxyamide | May 18, 2023 | Issued |
Array
(
[id] => 18595899
[patent_doc_number] => 20230270689
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-08-31
[patent_title] => TREATMENT OF ALZHEIMER'S DISEASE
[patent_app_type] => utility
[patent_app_number] => 18/143001
[patent_app_country] => US
[patent_app_date] => 2023-05-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14597
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -8
[patent_words_short_claim] => 30
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18143001
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/143001 | TREATMENT OF ALZHEIMER'S DISEASE | May 2, 2023 | Pending |
Array
(
[id] => 19447212
[patent_doc_number] => 20240307342
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-09-19
[patent_title] => Treatment of the adverse cardiovascular effects of cannabinoids
[patent_app_type] => utility
[patent_app_number] => 18/139917
[patent_app_country] => US
[patent_app_date] => 2023-04-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8333
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 31
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18139917
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/139917 | Treatment of the adverse cardiovascular effects of cannabinoids | Apr 25, 2023 | Abandoned |
Array
(
[id] => 18595904
[patent_doc_number] => 20230270694
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-08-31
[patent_title] => REDUCED SEDATION AND DISSOCIATION IN TREATING NEUROLOGICAL DISORDERS
[patent_app_type] => utility
[patent_app_number] => 18/133201
[patent_app_country] => US
[patent_app_date] => 2023-04-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 58994
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -29
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18133201
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/133201 | REDUCED SEDATION AND DISSOCIATION IN TREATING NEUROLOGICAL DISORDERS | Apr 10, 2023 | Pending |
Array
(
[id] => 18690849
[patent_doc_number] => 20230321007
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-12
[patent_title] => PHARMACOKINETICS OF NMDA RECEPTOR ANTAGONISTS
[patent_app_type] => utility
[patent_app_number] => 18/133189
[patent_app_country] => US
[patent_app_date] => 2023-04-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 59000
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -29
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18133189
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/133189 | PHARMACOKINETICS OF NMDA RECEPTOR ANTAGONISTS | Apr 10, 2023 | Pending |
Array
(
[id] => 18690913
[patent_doc_number] => 20230321077
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-12
[patent_title] => Combination treatment of dilated cardiomyopathy
[patent_app_type] => utility
[patent_app_number] => 18/132919
[patent_app_country] => US
[patent_app_date] => 2023-04-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4346
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 31
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18132919
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/132919 | Combination treatment of dilated cardiomyopathy | Apr 9, 2023 | Pending |
Array
(
[id] => 18690913
[patent_doc_number] => 20230321077
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-12
[patent_title] => Combination treatment of dilated cardiomyopathy
[patent_app_type] => utility
[patent_app_number] => 18/132919
[patent_app_country] => US
[patent_app_date] => 2023-04-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4346
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 31
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18132919
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/132919 | Combination treatment of dilated cardiomyopathy | Apr 9, 2023 | Pending |
Array
(
[id] => 18737893
[patent_doc_number] => 20230346794
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-11-02
[patent_title] => ADMINISTRATION AND DOSAGE OF DIAMINOPHENOTHIAZINES
[patent_app_type] => utility
[patent_app_number] => 18/131570
[patent_app_country] => US
[patent_app_date] => 2023-04-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 28070
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -28
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18131570
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/131570 | Administration and dosage of diaminophenothiazines | Apr 5, 2023 | Issued |
Array
(
[id] => 18522874
[patent_doc_number] => 20230233523
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-07-27
[patent_title] => ENHANCING AUTOPHAGY OR INCREASING LONGEVITY BY ADMINISTRATION OF UROLITHINS
[patent_app_type] => utility
[patent_app_number] => 18/130246
[patent_app_country] => US
[patent_app_date] => 2023-04-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 79557
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18130246
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/130246 | ENHANCING AUTOPHAGY OR INCREASING LONGEVITY BY ADMINISTRATION OF UROLITHINS | Apr 2, 2023 | Pending |
Array
(
[id] => 18522842
[patent_doc_number] => 20230233491
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-07-27
[patent_title] => COMBINATION OF DEXTROMETHORPHAN AND BUPROPION FOR TREATING DEPRESSION
[patent_app_type] => utility
[patent_app_number] => 18/194038
[patent_app_country] => US
[patent_app_date] => 2023-03-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 63736
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 80
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18194038
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/194038 | COMBINATION OF DEXTROMETHORPHAN AND BUPROPION FOR TREATING DEPRESSION | Mar 30, 2023 | Abandoned |
Array
(
[id] => 18509909
[patent_doc_number] => 20230225995
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-07-20
[patent_title] => COMBINATION OF DEXTROMETHORPHAN AND BUPROPION FOR TREATING DEPRESSION
[patent_app_type] => utility
[patent_app_number] => 18/188689
[patent_app_country] => US
[patent_app_date] => 2023-03-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 63736
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 79
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18188689
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/188689 | COMBINATION OF DEXTROMETHORPHAN AND BUPROPION FOR TREATING DEPRESSION | Mar 22, 2023 | Abandoned |
Array
(
[id] => 19903129
[patent_doc_number] => 12280113
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-04-22
[patent_title] => Ras inhibitors
[patent_app_type] => utility
[patent_app_number] => 18/188966
[patent_app_country] => US
[patent_app_date] => 2023-03-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 39
[patent_figures_cnt] => 42
[patent_no_of_words] => 70783
[patent_no_of_claims] => 4
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 7
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18188966
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/188966 | Ras inhibitors | Mar 22, 2023 | Issued |
Array
(
[id] => 19439930
[patent_doc_number] => 12090156
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-09-17
[patent_title] => Application of CB-839 in preparation of drug for inhibiting corneal neovascularization (CNV)
[patent_app_type] => utility
[patent_app_number] => 18/573439
[patent_app_country] => US
[patent_app_date] => 2023-02-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 1
[patent_figures_cnt] => 4
[patent_no_of_words] => 1460
[patent_no_of_claims] => 11
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 69
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18573439
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/573439 | Application of CB-839 in preparation of drug for inhibiting corneal neovascularization (CNV) | Feb 14, 2023 | Issued |
Array
(
[id] => 18418614
[patent_doc_number] => 20230173072
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-08
[patent_title] => PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM
[patent_app_type] => utility
[patent_app_number] => 18/159232
[patent_app_country] => US
[patent_app_date] => 2023-01-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 24954
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -24
[patent_words_short_claim] => 48
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18159232
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/159232 | Pharmaceutical compositions comprising meloxicam | Jan 24, 2023 | Issued |
Array
(
[id] => 18418614
[patent_doc_number] => 20230173072
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-08
[patent_title] => PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM
[patent_app_type] => utility
[patent_app_number] => 18/159232
[patent_app_country] => US
[patent_app_date] => 2023-01-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 24954
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -24
[patent_words_short_claim] => 48
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18159232
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/159232 | Pharmaceutical compositions comprising meloxicam | Jan 24, 2023 | Issued |
Array
(
[id] => 18550709
[patent_doc_number] => 20230248709
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-08-10
[patent_title] => Dosage Regimen for the Treatment of Cancer
[patent_app_type] => utility
[patent_app_number] => 18/152255
[patent_app_country] => US
[patent_app_date] => 2023-01-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11999
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18152255
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/152255 | Dosage regimen for the treatment of cancer | Jan 9, 2023 | Issued |
Array
(
[id] => 18375890
[patent_doc_number] => 20230150971
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-05-18
[patent_title] => PHARMACEUTICAL COMPOSITIONS OF 6-(2-(2H-TETRAZOL-5-YL)ETHYL)-6-FLUORODECAHYDROISOQUINOLINE-3-CARBOXYLIC ACID AND ESTER DERIVATIVES THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/147856
[patent_app_country] => US
[patent_app_date] => 2022-12-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 28653
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18147856
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/147856 | Pharmaceutical compositions of 6-(2-(2H-tetrazol-5-yl)ethyl)-6-fluorodecahydroisoquinoline-3-carboxylic acid and ester derivatives thereof | Dec 28, 2022 | Issued |